Calculated Boron Neutron Capture Dose Enhancement in ICRU 44 Brain with 252Cf
As 252Cf is a fast neutron emitter of relatively low average energy, there is potential to augment 252Cf brachytherapy with boron neutron capture (BNC) dose enhancement for treatment of malignant disease. 252Cf neutrons moderate within the human tissue and may be captured through the 10B(n,α + g)7Li nuclear reaction, Q = 2.79 MeV. Following this nuclear capture, a 477.6 keV photon is emitted 93.7% of the time by relaxation of the excited 7Li nucleus; however, the large majority of locally absorbed high-LET dose is deposited by the alpha particle and lithium ion. Consequently, it is possible that, with 10B-loaded drugs which have affinity towards malignant tumor cells, 252Cf brachytherapy may benefit from BNC dose enhancement. Calculations of the BNC dose enhancement are made for a variety of 10B loadings and sizes of phantom material composed of, as an illustration, of brain tissue, as well for tumors of diameter ranging from 2 to 6 cm. Additionally, the moderated 252Cf neutron energy spectrum is examined to demonstrate significant perturbation of the thermal neutron flux by increasing 10B loadings.
KeywordsDose Rate Fast Neutron Boron Neutron Capture Therapy Relative Biological Effectiveness Thermal Neutron Flux
Unable to display preview. Download preview PDF.
- 1.J.F. Briesmeister, Monte Carlo N-Particle transport code system, in: “MCNP4B User’s Manual,” LANL, Los Alamos, 1997.Google Scholar
- 2.A. Geist, A. Beguelin, J. Dongarra, W. Jiang, R. Manchek, and V. Sunderam. “PVM: Parallel Virtual Machine-A User’ Guide and Tutorial for Networked Parallel Computing,”The MIT Press, Cambridge, MA, 1994.Google Scholar
- 3.F. Van den Heuvel, M.J. Rivard, J.G. Wierzbicki, and D.P. Ragan, Implementation of distributed computing for Monte Carlo simulations using PVM in a low tech environment, in: “Medical Physics 1997,” Obninsk, 1997, pp. 90–91.Google Scholar
- 4.M.J. Rivard, J.G. Wierzbicki, and F. Van den Heuvel, Calculations of the 252Cf neutron spectrum in water for various positions and loadings of 10B and 157Gd, in: “American Nuclear Society Radiation Protection and Shielding Division: Technologies for the New Century,“ D.T. Ingersoll ed., ANS Inc., La Grange Park, IL, 1998, pp. 211–218.Google Scholar
- 7.L.A. Marjina, V.N. Kiseleva, M.I. Nechushkin, V.N. Chekhonadsky, and G.P. Elisyutin, The results of treatment of patients with endometrial cancer and carcinoma cervix using 252Cf HDR, in: “Californium-252: Isotope for 21st Century Radiotherapy,” J.G. Wierzbicki ed., Kluwer Academic Publishers, Netherlands, 1997, pp. 115–130.CrossRefGoogle Scholar
- 8.O.N. Denisenko, V.N. Ivanov, V.A. Kozlov, V.O. Sidorchenkov, A.A. Omarov, I.M. Chernichenko, and V.N. Chekhonadsky, Dosimetry and treatment planning in high dose rate 252Cf brachytherapy, ibid, 221–231.Google Scholar
- 9.A.G. Konoplyannikov, Biological effects of gamma-neutron radiation 252Cf or fission neutrons from the BR-10 reactor on tumor and normal cells and tissues, ibid, 257–261.Google Scholar